Medimaging Integrated Solution Inc.

2025 Annual General Shareholders' Meeting Minutes

Method of Meeting：Physical

Time：09:00 a.m., June 19, 2025

Place：2F, No.1, Industry E. Rd. II, Hsinchu Science Park, Hsinchu City (Newton Hall, HSPLINK)

The Number of Shares of Attendance：

Attending shareholders and proxy represented 20,467,565 shares (including 18,577,987 shares which attended through electronic voting) accounting for 58.88% of 34,758,155 shares, the Company's total outstanding shares.

Directors Present：Chairman：CHENG, CHU-MING

Director：CHEN, CHIN-YI, LEE, YU-TSUNG

Independent director：CHIU, CHIN-TAIN (Chairman of the Audit Committee), CHANG, MING-JYE, CHIANG, HUI-HUA

Attendee：LIU CHIEN-YU, CPA

Chairman：CHENG, CHU-MING

Recorder：KO, HUI-YU

1.The number of shareholders' representatives present has reached the statutory requirement, and the chairman called the meeting to order.

2.Chairman's Remarks: Omitted.

3.Report Items

(1). 2024 Business Report

Explanation: Please refer to attachment 1 for 2024 Business Report.

(2). Audit Committee's Review Report on the 2024 Financial Statements

Explanation: Please refer to attachment 2 for the Audit Committee's Review Report.

(3). Report on 2024 employees' compensation and directors' remuneration

Explanation:

I. According to Article 20 of the Articles of Association of the Company, "If the Company makes profits in the year, it shall appropriate 10% to 25% for employees' compensation and no more than 3% for directors' remuneration".

II. In the year of 2024, the Company proposes to allocate 10% according to Article 20 of the Articles of Association of the Company, which is NTD 1,592,198, as employees'

compensation, and the recipients of employees' compensation may include not only the full-time employees of the Company but also employees of controlled or affiliated companies who meet certain criteria. In addition, 0.5% will be allocated as directors' remuneration, which is NTD 79,609. According to the "Regulations Governing the Remuneration of Directors and Managers," the remuneration for directors will be calculated and allocated based on their degree of involvement in the company's operations and their contribution value. The remuneration has been reviewed and approved by the Compensation Committee and the Board of Directors, and all of the above-mentioned compensation and remuneration will be distributed in cash.

III. The above distributed amount is not different from the estimated amount of recognized expenses for the year 2024.

4.Proposed Resolutions

(1)(Proposed by the Board)

Proposal: 2024 Business Report and Financial Statements

Explanation:

Ⅰ. The Individual and Consolidated Financial Statements of the Company, including the balance sheet, income statement, statement of changes in shareholders' equity, and statement of cash flows, have been audited and issued an unqualified audit report by independent auditors, Ms. Tsai-Yen Chiang and Ms. Chien-Yu Liu, of PwC.

Ⅱ. The above Financial Statements and Business Report have been audited and issued a review report by the Audit Committee.

Ⅲ. Please refer to Attachment 1 and 3 of this handbook for the Business Report and Financial Statements.

Resolution: It was resolved that the above proposal be approved as proposed. The result is as follows:

Shares represented at the time of voting	Votes in favor	Votes against:	Votes invalid & abstained	% of the total represented share present
20,467,565	20,154,282	2,095	311,188	98.46%
Including electronic voting	18,573,194	2,095	2,698	

(2)(Proposed by the Board)

Proposal: 2024 earnings distribution

Explanation:

Ⅰ. The Company's statement of 2024 earnings distribution has been audited by the Audit Committee and determined by the Board of Directors on March 12th, 2025. Please refer to Attachment 4 of this handbook.

Ⅱ. The amount of cash dividends to be distributed, which is NT$ 17,379,078 (NT$ 0.5 per share), is calculated according to the proportion and rounded up by the unit of NT$1 (less than NT$1 is excluded), and the total amount of the distributive payments less than NT$1 are included in other income.

Ⅲ. In the event the number of outstanding shares is subsequently affected by changes in the Company's capital, resulting in the necessity to revise the shareholder's payout ratio, the Chairman shall be authorized to conduct such revision at its full discretion.

Ⅳ. After approved by the Shareholders' Meeting, the Chairman shall be authorized to determine the ex-dividend related matters.

Resolution: It was resolved that the above proposal be approved as proposed. The result is as follows:

Shares represented at the time of voting	Votes in favor	Votes against:	Votes invalid & abstained	% of the total represented share present
20,467,565	20,011,282	146,095	310,188	97.77%
Including electronic voting	18,430,194	146,095	1,698	

5. Discussion Items

(1)(Proposed by the Board)

Proposal: Amendments to the Articles of Incorporation

Explanation: Pursuant to the revisions to Paragraph 6, Article 14, of the Securities and Exchange Act- pay raise or allocation of bonus for entry-level employees using a certain percent of annual profits, the Company proposes to revise certain articles of the Articles of Incorporation. Please refer to Attachment 5 of this handbook for the comparison table of the above amendments.

Resolution: It was resolved that the above proposal be approved as proposed. The result is as follows:

Shares represented at the time of voting	Votes in favor	Votes against:	Votes invalid & abstained	% of the total represented share present
20,467,565	20,011,268	2,108	454,189	97.77%
Including electronic voting	18,430,180	2,108	145,699	

(2)(Proposed by the Board)

Proposal: Issuance of New Shares Transferred from Capital Surplus

Explanation:

Ⅰ. With the goal of expanding the Company's business scale and strengthening its financial structure, it is proposed that the Company issue new shares out of its capital surplus in the amount of NT$34,758,150, divided into 3,475,815 common shares with a par value of NT$10 each.

Ⅱ. The record date for this capital increase shall be set by the Board of Directors after approval of the capital increase by this Annual General Meeting and by the competent authority. 100 bonus shares will be allocated for every 1,000 shares. Shareholders can request to consolidate fractional shares with the Company's shareholder service agent within the period of five days from the share transfer suspension date. In the event that fractional shares are not consolidated within such time period, or where consolidation produces a fraction of less than one share, then such fractional shares will be converted to cash rounded to the nearest NT$ dollar in accordance with its par value and distributed to the shareholder. The Board of Directors shall authorize the Chairman to solicit specified persons to subscribe for accumulated fractional shares at a subscription price equal to par value.

Ⅲ. If the number of issued and outstanding shares of the Company subsequently changes due to share repurchase, share transfer, share conversion, share cancellation or other reasons, it is proposed that the Chairman shall be authorized to adjust the terms of this capital increase based on the actual number of outstanding shares on the record date, and to handle any related adjustments, revisions and/or amendments to the issuance therefor.

Ⅳ. The rights and obligations attached to the shares newly issued in this round of capital increase shall be the same as those of the existing shares of the Company.

Ⅴ. It is proposed that the Board of Directors shall be authorized with full powers to

take such actions in regards to this capital increase as may be necessitated due to the amendment of applicable laws or the opinions or comments of the relevant government authority.

Resolution: It was resolved that the above proposal be approved as proposed. The result is as follows:

Shares represented at the time of voting	Votes in favor	Votes against:	Votes invalid & abstained	% of the total represented share present
20,467,565	20,011,282	146,095	310,188	97.77%
Including electronic voting	18,430,194	146,095	1,698	

6.Extempore Motions:

Chairman:

The Company reports the status of the share buyback program resolved by the Board of Directors on April 17, 2025 (ROC Year 114) as follows:

Status of the Company's Share Buyback:

(1) Original maximum total amount allocated for share buyback: NT$374,232,636

(2) Original scheduled buyback period: 2025/04/18 to 2025/06/17

(3) Originally planned number of shares to be repurchased: 300,000 shares

(4) Original planned buyback price range: NT$65.00 to NT$75.00 per share. As the market price was below the lower limit of the price range, the Company planned to proceed with the buyback.

(5) Actual buyback period this time: None

(6) Actual number of shares repurchased: 0 shares

(7) Actual total amount of repurchased shares: NT$0

(8) Average repurchase price per share: NT$0

(9) Total number of treasury shares currently held: 0 shares

(10) Percentage of treasury shares held to total issued shares (%): 0%

(11) Reason for not completing the buyback:

During the buyback period, the international political and economic situation stabilized. As a result, there was no longer panic selling or irrationally low market prices. In fact, the market price mostly exceeded the originally planned buyback price range, making it impossible to complete the repurchase.

(As there were no other extempore motions upon the Chairman’s inquiry, the 2025 Annual General Meeting of Shareholders of the Company was declared closed.)

7.Adjournment: 09:21 a.m., June 19, 2025.

(No questions from shareholders for all iteams at this shareholders’ meeting.)

(These minutes of the shareholders’ meeting contain only a summary of the key discussion points. The full content shall be based on the official audio and video recordings of the meeting.)

Attachment 1

Medimaging Integrated Solution Inc.

2024 Business Report

1. 2024 Business Results

(1) Financial results

Unit：NT$ thousands

	2024	2023	Increases (decreases)	Change %
Operating revenue	538,920	537,148	1,772	0.33%
Gross profit	234,319	307,761	(73,442)	-23.86%
Net Operating Income	(3,783)	91,917	(95,700)	-104.12%
Net profit before tax	12,216	92,981	(80,765)	-86.86%
Net profit after tax	5,610	74,054	(68,444)	-92.42%

(2) Budget implementation: The Company did not disclose its financial forecasts of the year of 2024, so it is not necessary to publicly disclose the implementation of the budget.

(3) Financial profitability

Item		2024	2023
Financial structure	Liability to asset ratio (%)	45.25%	40.89%
	Long-term asset to real estate, plant and equipment ratio (%)	273.80%	375.59%
Debt-paying capability	Current ratio (%)	368.98%	566.47%
	Quick ratio (%)	266.55%	466.24%
Profitability	Return on assets (%)	0.93%	7.07%
	Return on equity (%)	0.73%	10.28%
	Net income ratio (%)	1.04%	13.79%
	Basic earnings per share (NTD)	0.16	2.2

(4) Overview of R&D

In the area of diagnostic scopes, we are collaborating with major international manufacturers to develop new types of fundus cameras and optical coherence tomography (OCT) devices. Regarding disposable endoscopes, following the development of a disposable cystoscope, our disposable bronchoscope has obtained U.S.

FDA 510(k) clearance. We are currently in exclusive licensing negotiations with the largest emergency medical services and acute care medical device distributor in the U.S., and we have also signed a distribution agreement with a well-known publicly listed Japanese company for the veterinary market. Additionally, we are entering the development of rigid endoscopes through the advancement of arthroscopes.
Subsidiary, Aitronics Inc., has partnered with the TASC Group to receive approval from the Ministry of Economic Affairs for an Advanced Technology R&D Program, focusing on the research and development of "high-precision non-invasive continuous glucose monitoring wearable device technology." In addition to its existing diagnostic consumables, Subsidiary, Lian Chan, is also developing airtight container products and continues to expand its production scope in medical consumables.
Looking ahead, R&D investment is expected to remain above 20% of annual revenue, with a continued focus on the development of innovative digital medical devices.

2. 2025Business Outlook

(1) Operating guideline

The company's core operations revolve around three key strategies: technological innovation, global expansion, and vertical integration. It continues to focus on three major markets—telemedicine, digital healthcare, and minimally invasive diagnostics and treatment. In addition to emphasizing product development to enhance market competitiveness, the company is also actively expanding its network of international partners, collaborating with leading global medical companies to drive worldwide product sales.
Furthermore, in response to brand clients' increasing demand for critical components, the company has extended upstream by building capabilities in micro camera module packaging and testing, as well as entering the field of plastic injection molding for medical device components. This one-stop service approach broadens the company's service offerings, scales up operations, and further strengthens its competitiveness.

(2) Sales Forecast

The Company will consider past experiences, current operational status, product sales plans, and factors such as future business environment and market conditions in setting internal operational goals.

(3) Significant Production and Sales Policies

The company focuses on the development of high-end medical imaging modules and

equipment, as well as disposable endoscopes, emphasizing advantages such as performance, safety, and real-time usability to meet clinical needs. In terms of market expansion, the company actively pursues international medical certifications and is deeply engaged in advanced medical markets such as Europe, the United States, and Japan.

Its sales strategy adopts a dual-track approach, combining OEM partnerships with major global medical device companies and development of its own brand, ensuring simultaneous growth in both market penetration and brand influence.

3. Future Development Strategies

(1) Deepening Global Market Presence: Continue expanding in the U.S., European, and Asian markets, while strengthening partnerships with leading international medical brands to increase market share.

(2) Expanding the Product Line: In addition to its existing disposable endoscope products, the company is integrating internal group resources to provide peripheral consumables required for minimally invasive surgeries, thereby broadening its range of products and services.

(3) Strengthening Smart Healthcare Development: Integrate artificial intelligence and big data analytics to develop automated diagnostic support functions, aiming to enhance the efficiency of medical diagnostics.

4. External Competition, Regulatory Environment, and Overall Business Environment Impact

The global development trends of telemedicine, digital healthcare, and minimally invasive diagnostics and treatment are clear, with growing support from national regulations and inclusion in insurance reimbursement systems helping to shape a more defined market structure. However, the following challenges still remain:

(1) Competitive Environment: The disposable endoscope market is becoming increasingly competitive, with major global medical brands actively expanding their presence. The company must continue to enhance its technological advantages and strengthen its market competitiveness through strategic brand partnerships.

(2) Regulatory Environment: Medical device regulations are stringent across countries, requiring the company to continuously invest resources in compliance and certification to ensure that its products meet regulatory standards in each market.

(3) Overall Business Environment: Global demand in the healthcare market continues to grow, but supply chain challenges, exchange rate fluctuations, and raw material price

volatility may impact the company’s profitability. The company will address these challenges through effective supply chain management and cost control measures.

Despite the global uncertainties around the world, the company will remain its entrepreneurship, continuing to focus on developing advanced smart medical equipment and solutions to enhance the company's R & D capabilities. We will collaborate with customers and suppliers to create more market opportunities, to generate higher shareholder value as a reward of shareholders.

CHENG, CHU-MING	CHENG, CHU-MING	HUANG, SHIH-TING
Chairman	President	Chief Accounting Officer

Attachment 2

Audit Committee’s review report

The Board of Directors has prepared the Company's 2024 Business Report, Financial Statements, and proposal of distribution of 2024 earnings. The CPA firm of PwC was retained to audit MiiS 's Financial Statements and has issued an audit report relating to the Financial Statements. The Business Report, Financial Statements, and proposal of distribution of 2024 earnings have been reviewed and determined to be correct and accurate by the Audit Committee members of Medimaging Integrated Solution Inc. According to relevant requirements of the Securities and Exchange Act and the Company Law, we hereby submit this report.

Medimaging Integrated Solution Inc.

Chairman of the Audit Committee: CHIU, CHIN-TAIN

March 12, 2025

Attachment 3

Independent Auditors' Report and 2024 Consolidated Financial Statements

INDEPENDENT AUDITORS' REPORT TRANSLATED FROM CHINESE

Independent Auditors' Report

(2025)Tsai-Sheng-Pao-Tzu No. 24004567

To the Board of Directors and Sharholders of Medimaging Integrated Solution, Inc.

Opinion

We have audited the accompanying consolidated financial statements of Medimaging Integrated Solution, Inc. and its subsidiaries (hereafter referred to as the MiiS Group), which comprise the consolidated balance sheet as of December 31, 2024, and December 31, 2023, and the consolidated statements of comprehensive income, consolidated statements of changes in equity, and consolidated statements of cash flows for the periods from January 1, 2024, to December 31, 2024, and from January 1, 2023, to December 31, 2023, as well as the notes accompanying the consolidated financial statements (including a summary of significant accounting policies).

In our opinion, based on our audits and the reports of other auditors, the accompanying consolidated financial statements present fairly, in all material respects, in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and the International Financial Reporting Standards (IFRS), International Accounting Standards (IAS), IFRIC Interpretations, and SIC Interpretations endorsed and issued into effect by the Financial Supervisory Commission, and sufficiently express the consolidated financial status of MiiS Group as of December 31, 2024, and December 31, 2023, and the consolidated financial performance and consolidated cash flows for the periods from January 1, 2024, to December 31, 2024, and from January 1, 2023, to December 31, 2023.

Basis for Opinion

We conducted our audits in accordance with the Regulations Governing Auditing and Attestation of Financial Statements by Certified Public Accountants and Standards on Auditingof the Republic of China. With our responsibility under such regulations and standards, we will further explain the responsibility of our audit of the consolidated financial statements. The independent certified public accountants (CPAs) of our accounting office have followed the Norm of Professional Ethics for Certified Public Accountants to remain impartial and independent from MiiS Group and carry out other responsibilities required by the Rules. We believe that we have obtained sufficient and pertinent audit evidence, which provides the basis of our audit opinions.

Key audit item

The key audit item refers to the most crucial element of our professional judgement about the audit conducted for the 2024 consolidated financial statements of MiiS Group. The item has been reflected in our overall audit of the consolidated financial statements and in the process to form our audit opinions; however, we do not express our opinion on the item individually.

A description of the key audit item of the consolidated financial statements of MiiS Group in 2024 is hereby provided:

Inventory Evaluation

Explanation

MiiS Group mainly manufactures and sells digital medical imaging diagnostic equipment products. The inventories are measured at the lower of cost and net realizable value; for detailed inventory evaluation policies, please refer to note 4(14) in the consolidated financial statements; for the uncertainties in accounting estimates for inventory evaluation, please refer to note 5(2) in the consolidated financial statements. As of December 31, 2024, the total inventory amount and allowance for inventory evaluation losses were NT$225,420,000 and NT$52,292,000, respectively.

Due to the significant value of MiiS Group's inventory, and the fact that human judgment is often required to determine the net realizable value of inventory exceeding the specified inventory age, outdated inventory, and obsolete inventory, we list inventory evaluation as one of the most important audit matters.

Corresponding Audit Procedures

The audit procedures performed by us are as follows:

1. Evaluate the rationality and consistency of the policy for provision of allowance for inventory valuation losses.
2. Obtain evaluation data on the lower of inventory cost and net realizable value prepared by the management, and verify that the logic of report preparation is consistent with the policy.
3. Sample check individual inventory item numbers for evaluation and verification of the net realizable value.
4. Check the rationality of the provision of allowance for inventory valuation losses.

Other Matter – Parent Company Only Financial Reports

MiiS Group has published parent company only financial statements for 2024 and 2023, and our CPAs have issued audited reports with unqualified opinions, which are on file for reference.

Responsibility of the management and governance unit for the consolidated financial statements

The responsibility of the management is to prepare the adequately expressed consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and the International Financial Reporting Standards (IFRS), International Accounting Standards (IAS), and the interpretations as well as the interpretation announcements recognized and announced effective by the Financial Supervisory Commission, and to maintain the internal controls required for the preparation of the consolidated financial statements so as to ensure that the consolidated financial statements do not have any material misstatement resulting from fraud or errors.

Unless the management plan is to liquidate MiiS Group or close the business or there are no other practical and feasible measures except liquidation or business closure, the responsibility of the management when preparing the consolidated financial statements includes assessment of MiiS Group's competence in continuing business operation, disclosure of relevant items, and adoption of the business continuation accounting basis.

The governance unit (including the Audit Committee) of MiiS Group is liable to supervise the financial reporting process.

Our responsibility for the audit of consolidated financial statements

The purpose of our audit of the consolidated financial statements is to obtain reasonable assurance as to whether any material misstatement resulting from fraud or errors exists in the overall consolidated financial statements, and issue the audit report. The reasonable assurance referred to here is a high degree of assurance. Nevertheless, the audit executed in accordance with the ROC auditing standards cannot guarantee that a material misstatement existing in the consolidated financial statements will be detected. A misstatement may result from fraud or errors. If the individual amount or compiled amount of a misstatement can be reasonably expected to impact the economic policy made by the user of the consolidated financial statements, it will be regarded as a material factor.

When conducting the audit in accordance with the generally accepted ROC auditing standards, we used our professional judgement and maintained a professional level of skepticism about dubious matters. We also executed the following tasks:

1. Recognize and assess the risk of a material misstatement resulting from fraud or errors in consolidated financial statements, design and take the appropriate coping strategy for the assessed risk, obtain sufficient and pertinent audit evidence as the basis of the audit opinions. Given that fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control, the risk of failure to detect a material misstatement resulting from fraud is higher than of one resulting from errors.

2. Understand the necessity of obtaining the internal control affiliated with the audit, so as to design the appropriate audit procedure for the current conditions. However, the purpose of this is not to express an opinion on the efficacy of MiiS Group's internal controls.

3. Assess the propriety of the accounting policy adopted by the management and the rationality of the accounting estimation and relevant disclosures.

4. Determine whether the business continuation accounting basis adopted by the management is proper, and whether the material dubious event or circumstance likely incurred from the competence of MiiS Group's continued business operation has any material uncertainty according to the acquired audit evidence. If we consider material uncertainty existent in such event or circumstance, we shall remind the user of the consolidated financial statements to pay attention to the relevant disclosures of the consolidated financial statements through our audit report, or modify the audit opinion when such disclosures are not applicable. Our conclusion is made according to the audit evidence acquired until the audit report day. However, the development of future events or circumstances is also likely to bring about MiiS Group' incompetence to continue its business operation.

5. Assess the overall representation, structure, and content of the consolidated financial statements (including the relevant notes) and check if the related transactions and events are adequately represented in the consolidated financial statements.

6. Acquire sufficient and pertinent audit evidence from the financial information of individual entities composing the MiiS Group so as to express opinions on the consolidated financial statements. We are responsible for the guidance, supervision, and execution of the Group's audit cases, and form the Group audit opinions.

The items communicated between us and the governance unit cover the planned audit scope and time and material audit findings (including the significant defects of internal control recognized in the audit process).

We also provide the governance unit with the fact that the personnel of our office who have been required for audit independence have complied with the independence statement stipulated in the Rules of Professional Ethics for Certified Public Accountants and communicated with the governance unit regarding any relations that are likely considered to impact CPA's independence and other items (including relevant protection measures).

According to the items communicated with the governance unit, we have determined the key item of our audit of MiiS Group's 2024 consolidated financial statements, and we have described the item in our audit report. Except for the specific items that are not allowed to be publicly disclosed as prescribed by laws and regulations or under a rare situation, we have decided not to communicate specific matters in our audit report because we have reason to believe that the negative influence of the communication is greater than the positive influence on the public interest.

PwC, Taiwan

Tsai-Yen Chiang

CPAs

Chien-Yu Liu

Financial Supervisory Commission
Approval File No.: Chin-Kuan-Cheng-Shen-Tzu No. 1060025097
Chin-Kuan-Cheng-Shen-Tzu No. 1090350620

March 12, 2025

Medimaging Integrated Solution Inc. and its Subsidiaries
Consolidated Balance Sheet
December 31, 2024 and 2023

In Thousands of New Taiwan Dollars

	Assets	Note	Dec. 31, 2024 Amount	%	Dec. 31, 2023 Amount	%
	Current assets					
1100	Cash and cash equivalents	6 (1)	$ 375,159	28	$ 474,332	36
1110	Financial assets measured at fair value through profit or loss－current	6 (2)	17	-	197	-
1136	Financial assets measured at amortized cost－current	6 (4)	5,000	-	183,817	14
1140	Contract assets－current	6 (20)	20,319	2	16,298	1
1150	Notes receivable – net	6 (5)	47	-	-	-
1170	Accounts receivable – net	6 (5)	167,478	12	81,396	6
1200	Other receivables		6,023	-	2,547	-
1220	Current Income Tax Assets		29	-	-	-
130X	Inventories	6 (6)	203,128	15	148,273	11
1410	Prepayments		17,714	1	15,308	1
1470	Other current assets		607	-	2,358	-
11XX	**Total current assets**		795,521	58	924,526	69
	Non-current assets					
1517	Financial assets measured at fair value through other comprehensive income－non-current	6 (3)	-	-	250	-
1535	Financial assets measured at amortized cost－non-current	6 (4)&8	2,431	-	2,431	-
1600	Property, plant, and equipment	6 (7)&8	416,564	31	313,483	23
1755	Right-of-use assets	6 (8)	48,055	4	41,887	3
1780	Intangible assets	6 (9)	26,060	2	16,957	1
1840	Deferred income tax assets	6 (27)	24,132	2	10,471	1
1915	Prepayments for business facilities	6 (30)	31,894	2	19,105	2
1990	Other non-current assets－other		11,479	1	11,516	1
15XX	**Total non-current assets**		560,615	42	416,100	31
1XXX	**Total assets**		$ 1,356,136	100	$ 1,340,626	100

(Continued to next page)

Medimaging Integrated Solution Inc. and its Subsidiaries
Consolidated Balance Sheet
December 31, 2024 and 2023

In Thousands of New Taiwan Dollars

	Liabilities and Equity	Note	Dec. 31, 2024 Amount	%	Dec. 31, 2023 Amount	%
	Current liabilities					
2100	Short-term liabilities	6 (10)	$ 25,000	2	$ -	-
2130	Contract liabilities－current	6 (20)	49,983	4	50,263	4
2170	Accounts payable		29,710	2	10,261	1
2200	Other payables	6 (11)	68,584	5	56,079	4
2230	Current tax liabilities		8,745	1	18,738	2
2250	Provisions－current	6 (16)	5,968	1	3,951	-
2280	Lease liabilities－current		4,481	-	3,580	-
2320	Long-term liabilities, current portion	6 (13)&8	18,983	1	18,597	1
2399	Other current liabilities－other		4,146	-	1,739	-
21XX	**Total current liabilities**		215,600	16	163,208	12
	Non-current liabilities					
2530	Corporate bonds payable	6 (12)	191,243	14	186,104	14
2540	Long-term borrowings	6 (13)&8	158,727	12	157,686	12
2550	Provisions－non-current	6 (16)	930	-	1,989	-
2570	Deferred income tax liabilities	6 (27)	2,411	-	-	-
2580	Lease liabilities－non-current		44,718	3	39,118	3
2670	Other non-current liabilities－other		40	-	20	-
25XX	**Total non-current liabilities**		398,069	29	384,917	29
2XXX	**Total liabilities**		613,669	45	548,125	41
	Equity attributable to owners of the parent					
	Share Capital	6 (17)				
3110	Common shares – share capital		347,582	25	345,842	26
	Capital surplus	6 (18)				
3200	Capital surplus		321,316	24	319,494	24
	Retained earnings	6 (19)				
3310	Legal reserve		50,583	4	43,178	3
3320	Special reserve		8,884	1	8,376	1
3350	Undistributed earnings		19,713	1	84,495	6
	Other equity					
3400	Other equity		(5,611)	(-)	(8,884)	(1)
31XX	**Total equity attributable to owners of the parent**		742,467	55	792,501	59
3XXX	**Total equity**		742,467	55	792,501	59
	Material contingent liabilities and unrecognized contractual commitments	9				
	Major subsequent events	11				
3X2X	**Total liabilities and equity**		$ 1,356,136	100	$ 1,340,626	100

The accompanying notes are an integral part of the consolidated financial statements; please see them together for reference.

Chairman: Chu-Ming Cheng Managerial Officer: Chu-Ming Cheng Accounting Officer: Shih-Ting Huang

Medimaging Integrated Solution Inc. and its Subsidiaries
Consolidated Statements of Comprehensive Income
For the years ended December 31, 2024 and 2023

（In Thousands of New Taiwan Dollars, except earnings per share）

	Item	Note	2024 Amount	2024 %	2023 Amount	2023 %
4000	Operating revenue	6 (20)&7	$ 538,920	100	$ 537,148	100
5000	Operating costs	6 (6)	(304,601)	(57)	(229,387)	(43)
5950	Gross operating profit, net		234,319	43	307,761	57
	Operating expenses	6(25) (26)				
6100	Selling expenses		(33,618)	(6)	(39,741)	(7)
6200	Administrative expenses		(62,436)	(12)	(48,551)	(9)
6300	Research and development expenses		(140,683)	(26)	(126,833)	(24)
6450	Expected credit impairment loss	12(2)	(1,365)	-	(719)	-
6000	Total operating expenses		(238,102)	(44)	(215,844)	(40)
6900	Operating income		(3,783)	(1)	91,917	17
	Non-operating revenue and expenses					
7100	Interest income	6 (21)	6,063	1	5,077	1
7010	Other income	6 (22)	6,039	1	2,129	-
7020	Other gains and loss	6 (23)	12,502	3	(2,295)	-
7050	Financial cost	6 (24)	(8,605)	(2)	(3,847)	1
7000	Total non-operating revenue and expenses		15,999	3	1,064	-
7900	**Net profit before tax**		12,216	2	92,981	17
7950	Income tax expenses	6 (26)	(6,606)	(1)	(18,927)	(3)
8200	**Profit for the period**		$ 5,610		$ 74,054	14
	Items that may be subsequently reclassified into profit or loss					
8316	Unrealized Gains and Losses on Equity Investments Measured at Fair Value through Other Comprehensive Income	6 (3)	$ 2,168	1	$ -	-
8361	Exchange differences resulting from translating the financial statements of a foreign operation		878	-	(508)	-
8300	**Other comprehensive income (net)**		$ 3,046	1	($ 508)	-
8500	**Total comprehensive income for the period**		$ 8,656	2	$ 73,546	14
	Basic earnings per share	6 (28)				
9750	Basic earnings per share		$	0.16	$	2.20
	Diluted earnings per share	6 (28)				
9850	Diluted earnings per share		$	0.16	$	2.18

The accompanying notes are an integral part of the consolidated financial statements; please see them together for reference.

Chairman: Chu-Ming Cheng Managerial Officer: Chu-Ming Cheng Accounting Officer: Shih-Ting Huang

Medimaging Integrated Solution Inc. and its Subsidiaries
Consolidated Statements of Changes in Equity
For the years ended December 31, 2024 and 2023

In Thousands of New Taiwan Dollars

	Note	Equity attributable to owners of the parent							
				Retained earnings			Other equity		
		Common shares-share capital	Capital surplus	Legal reserve	Special reserve	Undistributed earnings	Exchange differences resulting from translating the financial statements of a foreign operation	Unrealized profit or loss from financial assets measured at fair value through other comprehensive income	Total equity
2023									
Balance on Jan. 1, 2023		$ 332,277	$ 202,445	$ 36,176	$ 8,918	$ 76,710	($ 5,981)	($ 2,395)	$ 648,150
Profit for the period		-	-	-	-	74,054	-	-	74,054
Other comprehensive income for the period		-	-	-	-	-	(508)	-	(508)
Total comprehensive income for the period		-	-	-	-	74,054	(508)	-	73,546
Appropriation and distribution of retained earnings for 2022	6(19)								
Allocation to legal reserve		-	-	7,002	-	(7,002)	-	-	-
Allocation to special reserve		-	-	-	(542)	542	-	-	-
Cash dividend		-	-	-	-	(59,809)	-	-	(59,809)
Equity Component—Warrants Recognized from the Issuance of Convertible Bonds	6(12)(18)	-	21,811	-	-	-	-	-	21,811
Capital increase in cash	6(17)	12,500	91,170	-	-	-	-	-	103,670
Capital increase in cash – compensation costs reserved for employee stock options	6(15)(18)	-	2,709	-	-	-	-	-	2,709
Compensation costs of employee stock options	6(15)(18)	-	247	-	-	-	-	-	247
Exercise of employee stock option	6(15)(17)	1,065	1,065	-	-	-	-	-	2,130
Capital Surplus – Others	6(18)		47						47
Balance on Dec. 31, 2023		$ 345,842	$ 319,494	$ 43,178	$ 8,376	$ 84,495	($ 6,489)	($ 2,395)	$ 792,501
2024									
Balance on Jan. 1, 2024		$ 345,842	$ 319,494	$ 43,178	$ 8,376	$ 84,495	($ 6,489)	($ 2,395)	$ 792,501
Profit for the period		-	-	-	-	5,610	-	-	5,610
Other comprehensive income for the period	6(3)	-	-	-	-	-	878	2,168-	3,046
Total comprehensive income for the period		-	-	-	-	5,610	878	2,168-	8,656

The accompanying notes are an integral part of the consolidated financial statements; please see them together for reference.

Chairman: Chu-Ming Cheng Managerial Officer: Chu-Ming Cheng Accounting Officer: Shih-Ting Huang

Medimaging Integrated Solution Inc. and its Subsidiaries
Consolidated Statements of Changes in Equity
For the years ended December 31, 2024 and 2023

In Thousands of New Taiwan Dollars

		Equity attributable to owners of the parent							
				Retained earnings			Other equity		
	Note	Common shares-share capital	Capital surplus	Legal reserve	Special reserve	Undistributed earnings	Exchange differences resulting from translating the financial statements of a foreign operation	Unrealized profit or loss from financial assets measured at fair value through other comprehensive income	Total equity
Appropriation and distribution of retained earnings for 2023	6(19)								
Allocation to legal reserve		-	-	7,405	-	(7,405)	-	-	-
Reversal for special reserve		-	-	-	508	(508)	-	-	-
Cash dividend		-	-	-	-	(62,252)			(62,252)
Compensation costs of employee stock options	6(15)(18)		82						82
Exercise of employee stock option	6(15)(17)	1,740	1,740						3,480
Disposal of Equity Instruments Measured at Fair Value through Other Comprehensive Income	6(3)	-	-	-	-	(227)	-	227	-
Balance on Dec. 31, 2023		$ 347,582	$ 321,316	$ 50,583	$ 8,884	$ 19,713	($ 5,611)	-	$ 742,467

The accompanying notes are an integral part of the consolidated financial statements; please see them together for reference.

Chairman: Chu-Ming Cheng　　Managerial Officer: Chu-Ming Cheng　　Accounting Officer: Shih-Ting Huang

Medimaging Integrated Solution Inc. and its Subsidiaries
Consolidated Statements of Cash Flows
For the years ended December 31, 2024 and 2023

In Thousands of New Taiwan Dollars

	Note	Jan. 1 - Dec. 31, 2024	Jan. 1 - Dec. 31, 2023
Cash flows from operating activities			
Current net profit before tax		$ 12,216	$ 92,981
Adjustments			
Income and expense items			
Depreciation expenses	6(7)(8) (25)	50,274	28,604
Loss on disposal of property, plant, and equipment	6(7)(23)	882	-
Various amortization	6(9)(25)	4,417	3,029
Expected credit impairment loss	12(2)	1,365	719
Net loss on financial assets measured at fair value through profit or loss	6(23)	180	240
Remuneration cost for employee stock options	6(15) (26)	82	2,956
Interest income	6(21)	(6,063)	(5,077)
Interest expense	6(24)	8,605	3,847
Other item	6(22)	(403)	(461)
Changes in operating activities assets and liabilities			
Net changes in operating activities assets			
Contract assets		(3,941)	(4,473)
Notes receivable		175	-
Accounts receivable		(82,850)	(16,892)
Accounts receivable- related parties		-	40,709
Other receivables		(3,039)	683
Inventories		(36,778)	3,265
Prepayments		(1,750)	518
Other current assets		1,814	(2,276)
Long-term prepaid expenses		(1,968)	404
Net changes in operating activities liabilities			
Contract liabilities		(7,413)	49,508
Accounts payable		16,187	(17,860)
Accounts payables – related parties		(5)	-
Other payables		8,870	(3,712)
Provisions		946	2,160
Other current liabilities		2,331	1,260
Cash flows from operating activities		(35,839)	180,132
Interest received		6,063	5,077
Interest paid		(3,404)	(2,038)
Income tax paid		(17,219)	(14,221)
Net cash flows from operating activities		(50,399)	168,950

(Continued to next page)

Medimaging Integrated Solution Inc. and its Subsidiaries
Consolidated Statements of Cash Flows
For the years ended December 31, 2024 and 2023

In Thousands of New Taiwan Dollars

	Note	Jan. 1 - Dec. 31, 2024	Jan. 1 - Dec. 31, 2023
Cash flows from investing activities			
Disposal of financial assets at fair value through other comprehensive income	6(3)	$ 2,418	$ -
Acquisition of financial assets measured at amortized cost		(65,000)	(125,289)
Disposal of financial assets measured at amortized cost		244,817	-
Acquisition of subsidiaries (net of cash acquired)	6(29)	(54,641)	-
Acquisition of property, plant, and equipment	6(30)	(116,426)	(191,486)
Actual interest paid capitalized	6(7)(30)	(1,406)	(529)
Disposal of property, plant, and equipmen		2,817	-
Increased in refundable deposits		(69)	(600)
Decreased in refundable deposits		-	5
Acquisition of intangible assets	6(9)	(7,665)	(7,849)
Decrease (increase) in other prepayments		2,884	(3,462)
Net cash used in investing activities		7,729	(329,210)
Cash flows from financing activities			
Increased in short-term borrowings	6(31)	75,000	130,000
Decreased in short-term borrowings	6(31)	(61,000)	(130,000)
Proceeds from issuing corporate bonds	6(31)	-	205,679
Proceeds from long-term borrowings	6(31)	20,000	129,000
Repayments of long-term borrowings	6(31)	(25,972)	(18,337)
Increased in deposits received	6(31)	20	8
Payments of lease liabilities	6(31)	(6,339)	(2,588)
Cash dividend paid	6(19)	(62,250)	(59,808)
Capital increase in cash	6(17)	-	103,670
Exercise of employee stock option	6(15)(17)	3,480	2,130
Capital surplus – other	6(18)	-	47
Net cash flows from financing activities		(57,061)	(359,801)
Effect of exchange rate changes on cash and cash equivalents		558	(319)
Increase in cash and cash equivalents for the period		(99,173)	199,222
Cash and cash equivalents at the beginning	6(1)	474,332	275,110
Cash and cash equivalents at the end	6(1)	$ 375,159	$ 474,332

The accompanying notes are an integral part of the consolidated financial statements; please see them together for reference.

Chairman: Chu-Ming Cheng Managerial Officer: Chu-Ming Cheng Accounting Officer: Shih-Ting Huang

Independent Auditors' Report and 2024 Parent Company Only Financial Statements

INDEPENDENT AUDITORS' REPORT TRANSLATED FROM CHINESE

Independent Auditors' Report

(2025)Tsai-Sheng-Pao-Tzu No. 24004927

To the Board of Directors and Sharholders of Medimaging Integrated Solution, Inc.

Opinion

We have audited the accompanying parent only financial statements of Medimaging Integrated Solution, Inc., (the "Company") which comprise the parent company only balance sheet as of December 31, 2024, and December 31, 2023, and the parent company only statements of comprehensive income, parent company only statements of changes in equity, and parent company only statements of cash flows for the periods from January 1, 2024, to December 31, 2024, and from January 1, 2023, to December 31, 2023, as well as the notes accompanying the parent company only financial statements (including a summary of significant accounting policies).

In our opinion, the accompanying parent company only financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and its financial performance and its cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers.

Basis for Opinion

We conducted our audits in accordance with the Regulations Governing Auditing and Attestation of Financial Statements by Certified Public Accountants and the ROC auditing standards. With our responsibility under such regulations and standards, we will further explain the responsibility of our audit of the parent company only financial statements. The independent certified public accountants (CPAs) of our accounting office

have followed the Norm of Professional Ethics for Certified Public Accountants to remain impartial and independent from the Company and carry out other responsibilities required by the Rules. We believe that we have obtained sufficient and pertinent audit evidence, which provides the basis of our audit opinions.

Key audit item

The key audit item refers to the most crucial element of our professional judgement about the audit conducted for the 2024 parent company only financial statements of the Company. The item has been reflected in our overall audit of the parent company only financial statements and in the process to form our audit opinions; however, we do not express our opinion on the item individually.

A description of the key audit item of the parent company only financial statements of the Company in 2024 is hereby provided:

Inventory Evaluation

Explanation

The Companymainly manufactures and sells digital medical imaging diagnostic equipment products. The inventories are measured at the lower of cost and net realizable value; for detailed inventory evaluation policies, please refer to note 4(13) in the parent company only financial statements; for the uncertainties in accounting estimates for inventory evaluation, please refer to note 5(2) in the parent company only financial statements. As of December 31, 2024, the total inventory amount and allowance for inventory evaluation losses were NT$233,948,000 and NT$43,801,000, respectively.

Due to the significant value of the Company's inventory, and the fact that human judgment is often required to determine the net realizable value of inventory exceeding the specified inventory age, outdated inventory, and obsolete inventory, we list inventory evaluation as one of the most important audit matters.

Corresponding Audit Procedures

The audit procedures performed by us are as follows:

1. Evaluate the rationality and consistency of the policy for provision of allowance for inventory valuation losses.

2. Obtain evaluation data on the lower of inventory cost and net realizable value prepared

by the management, and verify that the logic of report preparation is consistent with the policy.

3. Sample check individual inventory item numbers for evaluation and verification of the net realizable value.

4. Check the rationality of the provision of allowance for inventory valuation losses.

Responsibility of the management and governance unit for the parent company only financial statements

The responsibility of the management is to prepare the adequately expressed consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and to maintain the internal controls required for the preparation of the parent company only financial statements so as to ensure that the consolidated financial statements do not have any material misstatement resulting from fraud or errors.

Unless the management plan is to liquidate the Company or close the business or there are no other practical and feasible measures except liquidation or business closure, the responsibility of the management when preparing the parent company only financial statements includes assessment of the Company's competence in continuing business operation, disclosure of relevant items, and adoption of the business continuation accounting basis.

The governance unit (including the Audit Committee) of the Company is liable to supervise the financial reporting process.

Our responsibility for the audit of parent company only financial statements

The purpose of our audit of the parent company only financial statements is to obtain reasonable assurance as to whether any material misstatement resulting from fraud or errors exists in the overall parent company only financial statements, and issue the audit report. The reasonable assurance referred to here is a high degree of assurance. Nevertheless, the audit executed in accordance with the ROC auditing standards cannot guarantee that a material misstatement existing in the parent company only financial statements will be detected. A misstatement may result from fraud or errors. If the individual amount or compiled amount of a misstatement can be reasonably expected to impact the economic policy made by the user of the parent company only financial

statements, it will be regarded as a material factor.

When conducting the audit in accordance with the Standards on Auditing of the Republic of China, we used our professional judgement and maintained a professional level of skepticism about dubious matters. We also executed the following tasks:

1. Recognize and assess the risk of a material misstatement resulting from fraud or errors in parent company only financial statements, design and take the appropriate coping strategy for the assessed risk, obtain sufficient and pertinent audit evidence as the basis of the audit opinions. Given that fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control, the risk of failure to detect a material misstatement resulting from fraud is higher than of one resulting from errors.

2. Understand the necessity of obtaining the internal control affiliated with the audit, so as to design the appropriate audit procedure for the current conditions. However, the purpose of this is not to express an opinion on the effectiveness of the Company's internal controls.

3. Assess the propriety of the accounting policy adopted by the management and the rationality of the accounting estimation and relevant disclosures.

4. Determine whether the business continuation accounting basis adopted by the management is proper, and whether the material dubious event or circumstance likely incurred from the competence of the Company's continued business operation has any material uncertainty according to the acquired audit evidence. If we consider material uncertainty existent in such event or circumstance, we shall remind the user of the parent company only financial statements to pay attention to the relevant disclosures of the parent company only financial statements through our audit report, or modify the audit opinion when such disclosures are not applicable. Our conclusion is made according to the audit evidence acquired until the audit report day. However, the development of future events or circumstances is also likely to bring about the Company's incompetence to continue its business operation.

5. Assess the overall representation, structure, and content of the parent company only financial statements (including the relevant notes) and check if the related transactions and events are adequately represented in the parent company only financial statements.

6. Acquire sufficient and pertinent audit evidence from the financial information of

individual entities composing the the Company so as to express opinions on the parent company only financial statements. We are responsible for the guidance, supervision, and execution of the parent company's audit cases, and form the parent company only financial statements audit opinions.

The items communicated between us and the governance unit cover the planned audit scope and time and material audit findings (including the significant defects of internal control recognized in the audit process).

We also provide the governance unit with the fact that the personnel of our office who have been required for audit independence have complied with the independence statement stipulated in the Rules of Professional Ethics for Certified Public Accountants and communicated with the governance unit regarding any relations that are likely considered to impact CPA's independence and other items (including relevant protection measures).

According to the items communicated with the governance unit, we have determined the key item of our audit of the Company's 2024 parent company only financial statements, and we have described the item in our audit report. Except for the specific items that are not allowed to be publicly disclosed as prescribed by laws and regulations or under a rare situation, we have decided not to communicate specific matters in our audit report because we have reason to believe that the negative influence of the communication is greater than the positive influence on the public interest.

PwC, Taiwan

Tsai-Yen Chiang

CPAs

Chien-Yu Liu

Financial Supervisory Commission
Approval File No.: Chin-Kuan-Cheng-Shen-Tzu No. 1060025097
Chin-Kuan-Cheng-Shen-Tzu No. 1090350620

March 12, 2025

Medimaging Integrated Solution, Inc.
Parent Company Only Balance Sheet
December 31, 2024 and 2023

In Thousands of New Taiwan Dollars

	Assets	Note	Dec. 31, 2024 Amount	%	Dec. 31, 2023 Amount	%
	Current assets					
1100	Cash and cash equivalents	6(1)	$ 321,787	25	$ 428,621	32
1110	Financial assets measured at fair value through profit or loss－current	6(2)	17	-	197	-
1136	Financial assets measured at amortized cost－current	6(4)	-	-	183,817	14
1140	Contract assets－current	6(20)	18,005	1	13,921	1
1170	Accounts receivable- net	6(5)	155,274	12	81,114	6
1180	Accounts receivable- net of the related parties	6(5)&7	71	-	167	-
1200	Other receivables		5,339	-	2,055	-
1210	Other receivables－related parties	7	423	-	620	-
130X	Inventories	6(6)	190,147	15	146,808	11
1410	Prepayments		12,348	1	13,012	1
1470	Other current assets		617	-	2,358	-
11XX	**Total current assets**		704,028	54	872,690	65
	Non-current assets					
1517	Financial assets measured at fair value through other comprehensive income－non-current	6(3)	-	-	250	-
1535	Financial assets measured at amortized cost－non-current	6(4)&8	2,431	-	2,431	-
1550	Investments accounted for using the equity method	6(7)	102,825	8	51,496	4
1600	Property, plant and equipment	6(8)&8	385,566	29	313,470	24
1755	Right-of-use assets	6(9)	38,092	3	41,059	3
1780	Intangible assets	6(10)	20,326	2	16,957	1
1840	Deferred income tax assets	6(27)	11,800	1	10,471	1
1915	Prepayments for business facilities	6(29)	31,939	2	19,105	1
1990	Other non-current assets－other		8,412	1	9,935	1
15XX	**Total non-current assets**		601,391	46	465,174	35
1XXX	**Total assets**		$ 1,305,419	100	$ 1,337,864	100

(Continued to next page)

Medimaging Integrated Solution, Inc.
Parent Company Only Balance Sheet
December 31, 2024 and 2023

In Thousands of New Taiwan Dollars

	Liabilities and Equity	Note	Dec. 31, 2024 Amount	%	Dec. 31, 2023 Amount	%
	Current liabilities					
2130	Contract liabilities－current	6(20)	$ 48,893	4	$ 50,190	4
2170	Accounts payable		24,070	2	10,261	1
2180	Accounts payable- related parties	7	813	-	-	-
2200	Other payables	6(11)	59,493	5	54,796	4
2220	Other payables- related parties	6(11)&7	10	-	-	-
2230	Current tax liabilities		8,745	1	18,738	2
2250	Provisions－current	6(16)	5,948	-	3,590	-
2280	Lease liabilities－current		1,686	-	2,535	-
2320	Long-term liabilities, current portion	6(13)&8	18,983	1	18,597	1
2399	Other current liabilities－other		3,937	-	1,739	-
21XX	**Total current liabilities**		172,578	13	160,446	12
	Non-current liabilities					
2530	Corporate bonds payable	6(12)	191,243	15	186,104	14
2540	Long-term borrowings	6(13)&8	158,727	12	157,686	12
2550	Provisions－non-current	6(16)	930	-	1,989	-
2570	Deferred income tax liabilities	6(27)	2,003	-	-	-
2580	Lease liabilities－non-current		37,431	3	39,118	3
2645	deposits received		40	-	20	-
25XX	**Total non-current liabilities**		390,374	30	384,917	29
2XXX	**Total liabilities**		562,952	43	545,363	41
	Equity					
	Share Capital	6(17)				
3110	Common shares – share capital		347,582	27	345,842	26
	Capital surplus	6(18)				
3200	Capital surplus		321,316	25	319,494	24
	Retained earnings	6(19)				
3310	Legal reserve		50,583	4	43,178	3
3320	Special reserve		8,884	1	8,376	1
3350	Undistributed earnings		19,713	1	84,495	6
	Other equity					
3400	Other equity		(5,611)	(1)	(8,884)	(1)
3XXX	**Total equity**		742,467	57	792,501	59
	Material contingent liabilities and unrecognized contractual commitments	9				
	Major subsequent events	11				
3X2X	**Total liabilities and equity**		$ 1,305,419	100	$ 1,337,864	100

The accompanying notes are an integral part of the parent company only financial statements; please see them together for reference.

Chairman: Chu-Ming Cheng Managerial Officer: Chu-Ming Cheng Accounting Officer: Shih-Ting Huang

Medimaging Integrated Solution Inc.
Parent Company Only Statements of Comprehensive Income
For the years ended December 31, 2024 and 2023

（In Thousands of New Taiwan Dollars, except earnings per share）

	Item	Note	2024 Amount	2024 %	2023 Amount	2023 %
4000	Operating revenue	6(20)&7	$ 485,074	100	$ 530,570	100
5000	Operating costs	6(6)&7	(245,969)	(51)	(224,740)	(42)
5900	Gross operating profit		239,105	49	305,830	58
5910	Unrealized profit from sales		(3,110)	(-)	(3,488)	(1)
5920	Realized profit from sales		3,488	1	4,691	1
5950	Gross operating profit, net		239,483	50	307,033	58
	Operating expenses	6(25) (26)				
6100	Selling expenses		(29,978)	(6)	(37,454)	(7)
6200	Administrative expenses		(53,220)	(11)	(46,184)	(9)
6300	Research and development expenses		(127,831)	(27)	(123,939)	(23)
6450	Expected credit impairment loss	12(2)	(1,076)	-	(434)	-
6000	Total operating expenses		(212,105)	(44)	(208,011)	(39)
6900	Operating income		27,378	6	99,022	19
	Non-operating revenue and expenses					
7100	Interest income	6(21)	5,692	1	5,011	1
7010	Other income	6(22)&7	6,427	1	1,898	-
7020	Other gains and loss	6(23)	13,305	3	(2,308)	-
7050	Financial cost	6(24)	(7,625)	(2)	(3,800)	1
7070	Share of profit (loss) of subsidiaries, associates and joint ventures accounted for using equity method	6(7)	(30,927)	(6)	(6,849)	(1)
7000	Total non-operating revenue and expenses		(13,128)	(3)	6,048	1
7900	**Net profit before tax**				92,974	18
7950	Income tax expenses	6(27)	(8,640)	(2)	(18,920)	(4)
8200	**Profit for the period**		$ 5,610	1	$ 74,054	14
	Other comprehensive income					
	Items not reclassified to profit or loss					
8316	Unrealized gains and losses on equity investments measured at fair value through other comprehensive income	6(3)	$ 2,168	1	$ -	-
	Items that may be subsequently reclassified into profit or loss					
8361	Exchange differences resulting from translating the financial statements of a foreign operation	6(7)	$ 878	-	($ 508)	-
8300	**Other comprehensive income (net)**		$ 3,046	1	($ 508)	-
8500	**Total comprehensive income for the period**		$ 8,656	2	$ 73,546	14
	Basic earnings per share	6(28)				
9750	Basic earnings per share		$	0.16	$	2.20
	Diluted earnings per share					
9850	Diluted earnings per share		$	0.16	$	2.18

The accompanying notes are an integral part of the parent company only financial statements; please see them together for reference.

Chairman: Chu-Ming Cheng　　Managerial Officer: Chu-Ming Cheng　　Accounting Officer: Shih-Ting Huang

Medimaging Integrated Solution Inc.
Parent Company Only Statements of Changes in Equity
For the years ended December 31, 2024 and 2023

In Thousands of New Taiwan Dollars

	Note	Common shares-share capital	Capital surplus	Retained earnings: Legal reserve	Retained earnings: Special reserve	Retained earnings: Undistributed earnings	Other equity: Exchange differences resulting from translating the financial statements of a foreign operation	Other equity: Unrealized profit or loss from financial assets measured at fair value through other comprehensive income	Total equity
2023									
Balance on Jan. 1, 2023		$ 332,277	$ 202,445	$ 36,176	$ 8,918	$ 76,710	($ 5,981)	($ 2,395)	$ 648,150
Profit for the period		-	-	-	-	74,054	-	-	74,054
Other comprehensive income for the period		-	-	-	-	-	(508)	-	(508)
Total comprehensive income for the period		-	-	-	-	74,054	(508)	-	73,546
Appropriation and distribution of retained earnings for 2022	6(19)								
Allocation to legal reserve		-	-	7,002	-	(7,002)	-	-	-
Allocation to special reserve		-	-		(542)	542	-	-	-
Cash dividend		-	-	-	-	(59,809)	-	-	(59,809)
Equity Component—Warrants Recognized from the Issuance of Convertible Bonds	6(12)(18)	-	21,811	-	-	-	-	-	21,811
Capital increase in cash	6(17)	12,500	91,170	-	-	-	-	-	103,670
Capital increase in cash -Compensation costs reserved for employee stock options	6(15)(18)	-	2,709	-	-	-	-	-	2,709
Compensation costs of employee stock options	6(15)(18)	-	247	-	-	-	-	-	247
Exercise of employee stock option	6(15)(17)	1,065	1,065	-	-	-	-	-	2,130
Capital Surplus – Others	6(18)	-	47	-	-	-	-	-	47
Balance on Dec. 31, 2023		$ 345,842	$ 319,494	$ 43,178	$ 8,376	$ 84,495	($ 6,489)	($ 2,395)	$ 792,501
2024									
Balance on Jan. 1, 2024		$ 345,842	$ 319,494	$ 43,178	$ 8,376	$ 84,495	($ 6,489)	($ 2,395)	$ 792,501
Profit for the period		-	-	-	-	5,610	-	-	5,610
Other comprehensive income for the period	6(3)	-	-	-	-	-	878	2,168	3,046
Total comprehensive income for the period		-	-	-	-	5,610	878	2,168	8,656
Appropriation and distribution of retained earnings for 2023	6(19)								
Allocation to legal reserve		-	-	7,405	-	(7,405)	-	-	-
Reversal for special reserve		-	-	-	508	(508)	-	-	-

The accompanying notes are an integral part of the parent company only financial statements; please see them together for reference.

Chairman: Chu-Ming Cheng Managerial Officer: Chu-Ming Cheng Accounting Officer: Shih-Ting Huang

Medimaging Integrated Solution Inc.
Parent Company Only Statements of Changes in Equity
For the years ended December 31, 2024 and 2023

In Thousands of New Taiwan Dollars

				Retained earnings			Other equity		
	Note	Common shares-share capital	Capital surplus	Legal reserve	Special reserve	Undistributed earnings	Exchange differences resulting from translating the financial statements of a foreign operation	Unrealized profit or loss from financial assets measured at fair value through other comprehensive income	Total equity
Cash dividend		-	-	-	-	(62,252)	-	-	(62,252)
Compensation costs of employee stock options	6(15)(18)	-	82	-	-	-	-	-	82
Exercise of employee stock option	6(15)(17)	1,740	1,740	-	-	-	-	-	3,480
Disposal of Equity Instruments Measured at Fair Value through Other Comprehensive Income	6(3)	-	-	-	-	(227)	-	227	-
Balance on Dec. 31, 2024		$ 347,582	$ 321,316	$ 50,583	$ 8,884	$ 19,713	($ 5,611)	$ -	$ 742,467

The accompanying notes are an integral part of the parent company only financial statements; please see them together for reference.

Chairman: Chu-Ming Cheng Managerial Officer: Chu-Ming Cheng Accounting Officer: Shih-Ting Huang

Medimaging Integrated Solution, Inc.
Parent Company Only Statements of Cash Flows
For the years ended December 31, 2024 and 2023

In Thousands of New Taiwan Dollars

	Note	Jan. 1 - Dec. 31, 2024	Jan. 1 - Dec. 31, 2023
Cash flows from operating activities			
Current net profit before tax		$ 14,250	$ 92,974
Adjustments			
Income and expense items			
Depreciation expenses	6(8)(9)(25)	34,115	27,715
Various amortization	6(10)(25)	4,296	3,029
Expected credit impairment loss	12(2)	1,076	434
Net loss on financial assets measured at fair value through profit or loss	6(23)	180	240
Remuneration cost for employee stock options	6(15)	82	2,956
Interest income	6(21)	(5,692)	(5,011)
Interest expense	6(24)	7,625	3,800
Share of profit or loss of subsidiaries using the equity method	6(7)	30,927	6,849
Unrealized profit from sales		3,110	3,488
Realized profit from sales		(3,488)	(4,691)
Payable transferred to other income		(2)	211
Changes in operating activities assets and liabilities			
Net changes in operating activities assets			
Contract assets		(4,084)	(4,104)
Accounts receivable		(75,236)	(17,055)
Accounts receivable- related parties		96	45,592
Other receivables		(3,284)	672
Other receivables- related parties		197	(620)
Inventories		(43,339)	(243)
Prepayments		664	445
Other current assets		1,741	(2,276)
Long-term prepaid expenses		(1,333)	578
Net changes in operating activities liabilities			
Contract liabilities		(1,297)	49,490
Accounts Payable		13,809	(17,860)
Accounts Payable- related parties		813	-
Other payables		5,719	(3,028)
Other payables- related parties		10	-
Provisions		1,299	1,842
Other current liabilities		2,198	1,260
Cash flows from operating activities		(15,548)	186,265
Interest received		5,692	5,011
Interest paid		(2,444)	(1,991)
Income tax paid		(17,959)	(14,214)
Net cash flows from operating activities		(30,259)	175,071

(Continued to next page)

Medimaging Integrated Solution, Inc.
Parent Company Only Statements of Cash Flows
For the years ended December 31, 2024 and 2023

In Thousands of New Taiwan Dollars

	Note	Jan. 1 - Dec. 31, 2024	Jan. 1 - Dec. 31, 2023
Cash flows from investing activities			
Disposal of financial assets at fair value through other comprehensive income	6(3)	$ 2,418	$ -
Acquisition of financial assets measured at amortized cost		(60,000)	(125,289)
Disposal of financial assets measured at amortized cost		243,817	-
Acquisition of investments accounted for using the equity method	6(7)	(81,000)	(29,000)
Acquisition of property, plant and equipment	6(29)	(115,735)	(191,486)
Actual interest paid capitalized	6(8)(29)	(1,406)	(529)
Increased in refundable deposits		(55)	-
Decreased in refundable deposits		-	5
Acquisition of intangible asset	6(10)	(7,665)	(7,849)
Increased in other prepayments		2,910	(3,462)
Net cash used in investing activities		(16,716)	(357,081)
Cash flows from financing activities			
Increased in short-term borrowings	6(30)	-	130,000
Decreased in short-term borrowings	6(30)	-	(130,000)
Proceeds from issuing corporate bonds	6(30)	-	205,679
Proceeds from long-term borrowings	6(30)	20,000	129,000
Repayments of long-term borrowings	6(30)	(18,573)	(18,337)
Increased in deposits received	6(30)	20	8
Payments of lease liabilities	6(30)	(2,536)	(1,821)
Cash dividend paid	6(19)	(62,250)	(59,808)
Capital increase in cash	6(17)	-	103,670
Exercise of employee stock option	6(15)(17)	3,480	2,130
Capital surplus-other	6(18)	-	47
Net cash flows from financing activities		(59,859)	360,568
Increase in cash and cash equivalents for the period		(106,834)	178,029
Cash and cash equivalents at the beginning	6(1)	428,621	250,592
Cash and cash equivalents at the end	6(1)	$ 321,787	$ 428,621

The accompanying notes are an integral part of the parent company only financial statements; please see them together for reference.

Chairman: Chu-Ming Cheng Managerial Officer: Chu-Ming Cheng Accounting Officer: Shih-Ting Huang

Attachment 4

Medimaging Integrated Solution Inc.

2024 Earnings Distribution Table

Unit: NT$

Items	Amount	Note
Earnings in 2023 available for distribution	14,329,912	
Plus：Net Income of 2024	5,609,822	
Less：Disposal of equity instruments measured at fair value through other comprehensive income	(227,869)	
Less：Legal reserve (10%)	(538,195)	
Plus：Reversal of special reserve	3,273,880	
Retained earnings available for distribution as of December 31, 2024	22,447,550	
Distribution Item:		
Cash Dividends to Common Share Holders	(17,379,078)	NT$ 0.5 per share
Subtotal	(17,379,078)	
Unappropriated retained earnings	5,068,472	
Note：The cash dividends to common share holders will be rounded down to NT$1 (any amount under NT$1 will be discarded), and the remaining fraction will be incorporated into other revenues of the Company.		

CHENG, CHU-MING	CHENG, CHU-MING	HUANG, SHIH-TING
Chairman	President	Chief Accounting Officer

Attachment 5

Medimaging Integrated Solution Inc.

Articles of Incorporation

Before and After Revision

After the revision	Before the revision	Description
Article 20 The Company shall allocate 10% to 25% of profit as employees' compensation and no more than 3% of profit as directors' compensation for each profitable fiscal year after offsetting any cumulative losses. The amount of employee' compensation mentioned above shall include no less than 5% allocated as compensation for grassroots employees. The aforementioned employees' compensation will be distributed in shares or cash. The employees of the Company's subsidiaries who fulfill specific requirements may be granted such compensation. The proposal for the distribution of employee' compensation and directors' compensation shall be reported to the shareholders' meeting.	Article 20 The Company shall allocate 10% to 25% of profit as employees' compensation and no more than 3% of profit as directors' compensation for each profitable fiscal year after offsetting any cumulative losses. The aforementioned employees' compensation will be distributed in shares or cash. The employees of the Company's subsidiaries who fulfill specific requirements may be granted such compensation.	Handled in accordance with Article 14, Paragraph 6 of the Securities and Exchange Act.
Article 23 This Articles of Association was concluded on July 20, 2010 The 1st revision was made on March 23, 2011 The 2nd revision was made on April 25, 2011 The 3rd revision was made on July 1, 2011 The 4th revision was made on January 26, 2012	Article 23 This Articles of Association was concluded on July 20, 2010 The 1st revision was made on March 23, 2011 The 2nd revision was made on April 25, 2011 The 3rd revision was made on July 1, 2011 The 4th revision was made on January 26, 2012	Add revision date.

The 5th revision was made on June 20, 2013 The 6th revision was made on May 2, 2014 The 7th revision was made on November 27, 2015 The 8th revision was made on June 15, 2016 The 9th revision was made on June 25, 2018 The 10th revision was made on June 23, 2020 The 11h revision was made on December 10, 2020 The 12th revision was made on July 2, 2021 The 13th revision was made on June 17, 2022 The 14th revision was made on June 19, 2025	The 5th revision was made on June 20, 2013 The 6th revision was made on May 2, 2014 The 7th revision was made on November 27, 2015 The 8th revision was made on June 15, 2016 The 9th revision was made on June 25, 2018 The 10th revision was made on June 23, 2020 The 11h revision was made on December 10, 2020 The 12th revision was made on July 2, 2021 The 13th revision was made on June 17, 2022	